THZ1: Towards KRAS mutation-based precision medicine against pancreatic ductal adenocarcinoma

Keywords

KRAS mutants / pancreatic ductal adenocarcinoma / PI3K/AKT/mTOR signalling / precision oncology / super-enhancer / THZ1

References

[1] Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68:130-139.

[2] Huang L, Jansen L, Balavarca Y, et al. Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer-more is better? a large international population-based cohort study. Ann Surg. 2021;274:e554-e563.

[3] Huang L, Lv Y, Guan S, et al. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study. J Transl Med. 2024;22:184.

[4] Huang L, Yuan X, Zhao L, et al. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. BJS Open. 2023;7:zrad031.

[5] Wijnen R, Pecoraro C, Carbone D, et al. Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). Cancers. 2021;13:4389.

[6] Huang C-S, You X, Dai C, et al. Targeting super-enhancers via nanoparticle-facilitated BRD4 and CDK7 inhibitors synergistically suppresses pancreatic ductal adenocarcinoma. Adv Sci. 2020;7:1902926.

[7] Huang L, Yang H, Chen K, et al. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: a hypothesis-generating study. Clin Transl Med. 2023;13:e1500.

[8] Stanciu S, Ionita-Radu F, Stefani C, et al. Targeting PI3K/AKT/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects. Int J Mol Sci. 2022;23:10132.

[9] Heisey DAR, Jacob S, Lochmann TL, et al. Pharmaceutical interference of the EWS-FLI1–driven transcriptome by cotargeting H3K27ac and RNA polymerase activity in Ewing sarcoma. Mol Cancer Ther. 2021;20:1868-1879.

[10] Huang L, Balavarca Y, Van Der Geest L, et al. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. BMC Med. 2019;17:66.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.